Fingolimod effect on disability progression in primary progressive multiple sclerosis patients with inflammatory activity: A post-hoc subgroup analysis of the INFORMS study

被引：0
|
作者：
Wolinsky, J. S. [1 ]
Cree, B. A. C. [2 ]
Freedman, M. S. [3 ]
Hartung, H. -P. [4 ]
Lublin, F. [5 ]
Miller, D. H. [6 ]
Montalban, X. [7 ]
Uitdehaag, B. [8 ]
Weiner, H. [9 ]
Lubetzki, C. [10 ]
Putzki, N. [11 ]
Li, B. [12 ]
Haring, D. A. [11 ]
Merschhemke, M. [11 ]
Kappos, L. [13 ]
机构：
[1] Texas Hlth Sci Ctr, Houston, TX USA
[2] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
[3] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[7] Hosp San Pedro Univ Vall dHebron, Barcelina, Spain
[8] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[9] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[10] Univ Paris 06, Salpetriere Hosp, Paris, France
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Univ Basel, Univ Hosp, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
基金：
新加坡国家研究基金会; 美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1283
引用
收藏
页码：679 / 680
页数：2
相关论文
共 50 条
  • [1] Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis
    Miller, David
    Cree, Bruce
    Dalton, Catherine
    Freedman, Mark
    Hartung, Hans
    Kappos, Ludwig
    Lubetzki, Catherine
    Lublin, Fred
    MacManus, David
    Montalban, Xavier
    Weiner, Howard
    Wolinsky, Jerry
    De Vera, Ana
    Kornyeyeva, Elena
    Li, Bingbing
    Pirozzi, Claudia
    von Rosenstiel, Philipp
    Polman, Chris
    NEUROLOGY, 2013, 80
  • [2] Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study
    Polman, C. H.
    Cree, B.
    Freedman, M. S.
    Hartung, H. -P.
    Holdbrook, F.
    Kappos, L.
    Kornyeyeva, E.
    Lubetzki, C.
    Lublin, F. D.
    Miller, D. H.
    Montalban, X.
    Pirozzi, C.
    Weiner, H. L.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 437 - 438
  • [3] Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial
    Fox, Edward
    Lublin, Fred
    Wolinsky, Jerry
    Cohen, Jeffery
    Meng, Xiangyi
    Ziehn, Marina
    Kolodny, Scott
    Putzki, Norman
    Cree, Bruce A. C.
    NEUROLOGY, 2018, 90
  • [4] Disease activity impacts disability progression in primary progressive multiple sclerosis
    Marrodan, M.
    Bensi, C.
    Pappolla, A.
    Rojas, J. I.
    Gaitan, M. I.
    Ysrraelit, M. C.
    Negrotto, L.
    Fiol, M. P.
    Patrucco, L.
    Cristiano, E.
    Farez, M. F.
    Correale, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [5] Effects of Fingolimod on Disability Progression in Patients with Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II
    Bergvall, Niklas
    Sfikas, Nikolaos
    Chin, Peter
    Tomic, Davorka
    Von Rosenstiel, Philipp
    Alsop, Jonathan
    Cutter, Gary
    Calabresi, Peter
    Jeffery, Douglas
    Lublin, Fred
    Kappos, Ludwig
    NEUROLOGY, 2013, 80
  • [6] Differences between Progressing and Stable Patients with Primary Progressive Multiple Sclerosis in INFORMS (Fingolimod vs Placebo)
    Wolinsky, Jerry S.
    Lublin, Fred
    Weiner, Howard
    Li, Bingbing
    Haering, Dieter A.
    Merschhemke, Martin
    Putzki, Norman
    Miller, David H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 15 - 15
  • [7] The relationship between MRI lesion activity, relapses and disability progression in relapsing-remitting multiple sclerosis: a post-hoc analysis from the PRISMS study
    Sandberg-Wallheim, M
    MULTIPLE SCLEROSIS, 2005, 11 : S154 - S154
  • [8] Assessing a predictive score for disease activity in secondary progressive multiple sclerosis: post-hoc analysis of data from the SPECTRIMS study
    Freedman, M.
    Ben-Amor, A-F
    Aycardi, E.
    Issard, D.
    Casset-Semanaz, F.
    Sormani, M-P
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 403 - 403
  • [9] Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
    Miller, David H.
    Lublin, Fred D.
    Sormani, Maria Pia
    Kappos, Ludwig
    Yaldizli, Ozgur
    Freedman, Mark S.
    Cree, Bruce A. C.
    Weiner, Howard L.
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    MacManus, David G.
    Yousry, Tarek A.
    Wheeler-Kingshott, Claudia A. M. Gandini
    Li, Bingbing
    Putzki, Norman
    Merschhemke, Martin
    Haring, Dieter A.
    Wolinsky, Jerry S.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (03): : 346 - 356
  • [10] Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensenn, Per
    Vermersch, Patrick
    Hicking, Christine
    Dangond, Fernando
    Ciovannoni, Gavin
    NEUROLOGY, 2016, 86
12345